A urine drug screen can provide useful clinical information, but a positive or negative result rarely tells the whole story. What was included in the panel, when the sample was collected, the testing method used, and the patient’s medications can all influence what the result means.
What Is a Urine Drug Screen?
A urine drug screen, often shortened to UDS, is a laboratory test used to look for selected drugs or their metabolites in urine. Metabolites are substances produced as the body processes a drug. Because these compounds may remain detectable after the immediate effects of a drug have passed, urine testing can help identify recent exposure without showing exactly when the drug was taken or how impaired a person may have been.
According to MedlinePlus, urine is the most commonly used sample for drug testing. Testing may be used during emergency care, medication monitoring, pain treatment, substance use disorder treatment, and other situations where drug exposure could affect care. A UDS alone, however, cannot diagnose a substance use disorder.
What Can a Urine Drug Screen Detect?
A UDS does not automatically test for every drug. The substances detected depend on the panel and laboratory method being used. Depending on the test, a panel may look for amphetamines, cocaine metabolites, cannabinoids, opiates, benzodiazepines, barbiturates, PCP, or other substances. If a particular drug matters to the clinical decision, the healthcare professional should confirm that it is actually included in the ordered panel.
Opioid testing deserves particular attention. The CDC opioid prescribing guideline explains that a standard opiate-class immunoassay primarily detects morphine-related compounds and may not detect synthetic or semisynthetic opioids. Fentanyl and methadone, for example, are not detected by a standard opiate screen, while oxycodone and buprenorphine may also require specific testing. This is why a negative routine opiate screen does not necessarily rule out exposure to those drugs.
How Is a UDS Performed?
The patient usually provides a urine sample at a physician office, hospital, laboratory, treatment center, or another approved collection site. Patients should tell the healthcare professional about prescription medications, over-the-counter medicines, and supplements because some substances can affect screening results.
The initial test is often a presumptive immunoassay. It is useful for quickly screening one or more drug classes, but an unexpected result may need more specific testing. The U.S. Food and Drug Administration notes that medicines, foods, supplements, sample handling, and testing technique can affect preliminary results. A positive screening result therefore should not automatically be treated as a final answer when the result could lead to an important clinical or nonclinical decision.
Screening and Confirmation Serve Different Purposes
Presumptive screening is designed to identify whether a targeted drug or drug class may be present. When greater specificity is needed, a laboratory may use a definitive method such as chromatography combined with mass spectrometry to identify individual drugs or metabolites more precisely.
Practical point: Review the substances included in the ordered panel before interpreting the result. A test cannot identify a substance it was not designed to detect.
The CDC’s toxicology-testing guidance recommends considering confirmatory testing when an unexpected screening result could significantly influence patient care, when a specific drug cannot be identified by the standard screen, or when a result requires clarification.
What Does a Positive UDS Result Mean?
A positive screening result means that the test detected a targeted substance or drug class at or above the assay’s cutoff. It does not automatically mean that a patient misused a drug, has an addiction, or was impaired when the specimen was collected. A prescribed medication may explain the finding, and some screening assays can also produce false-positive results.
Before making a major treatment decision, the care team should review the patient’s medication history, symptoms, recent treatments, the substances included in the panel, and whether confirmatory testing is appropriate.
What Does a Negative UDS Result Mean?
A negative result means that the substances tested for were not found at a concentration high enough to meet the test’s positive cutoff. It does not always prove that a drug was never used. The substance may not have been included in the panel, the concentration may have been too low, or the sample may have been collected outside the drug’s detection window.
This is especially important when an expected prescription drug is not detected. The result may reflect the timing of the sample or the limitations of the assay rather than automatically proving that a patient is not taking medication as prescribed.
Who Uses UDS Results in Patient Care?
Urine drug testing can support decisions across several areas of healthcare. Primary care clinicians may use it during medication monitoring, while pain-management providers may use toxicology testing when managing certain opioid therapies. Addiction-medicine clinicians and substance use treatment teams may use drug testing to support assessment and treatment planning, as discussed in SAMHSA’s clinical drug-testing guidance for primary care and its clinical addiction-medicine resource.
UDS results may also be reviewed by psychiatrists and behavioral health teams, emergency and hospital clinicians, and other professionals responsible for medication monitoring or substance use disorder treatment. Clinical pharmacists may participate as part of medication-management or multidisciplinary care teams. In every setting, the result should be considered together with the rest of the patient’s clinical information.
Common CPT Codes for Presumptive Urine Drug Testing
Coding depends on how the presumptive test is actually performed, not simply on how many substances appear on the panel. The current CMS Billing and Coding: Urine Drug Testing article identifies CPT codes 80305, 80306, and 80307 for presumptive testing. The descriptions below are plain-language summaries; practices should verify the current CPT code set and individual payer requirements before submitting a claim.
| CPT code | Plain-language billing use |
| 80305 | Presumptive testing performed with devices that are read by direct visual observation, such as certain cups, cards, strips, or similar devices. |
| 80306 | Presumptive testing using a visual testing device where an instrument assists with reading or interpreting the result. |
| 80307 | Presumptive drug testing performed using an instrumented laboratory chemistry analyzer. |
CMS states that only one presumptive drug-testing code should be billed per patient per date of service, regardless of how many drug classes are tested. CMS applies a similar one-per-day rule to definitive testing. For Medicare definitive drug testing, the same CMS article also identifies HCPCS Level II codes G0480 through G0483 and G0659. These are HCPCS codes, not CPT codes, and the appropriate code depends on the testing performed and applicable coverage policy.
Documentation Matters as Much as Code Selection
UDS billing should begin with a clear clinical reason for the test. CMS guidance states that the medical record should support medical necessity, and the written order should identify the drugs or drug classes being tested. Documentation should also make it clear who ordered the test, why it was needed, and how the result relates to the patient’s treatment or monitoring plan.
A correct CPT code cannot fix missing medical necessity or an unclear order. This is where clinical documentation and revenue cycle workflows need to connect. RCMGen’s physician and clinic revenue cycle services include medical coding, claim scrubbing, claims submission, denial management, payment posting, and accounts receivable follow-up.
RCMGen supports billing workflows for the practices, clinics, physician groups, and healthcare organizations where UDS may be part of care, including primary care, pain management, addiction medicine, psychiatry and behavioral health, emergency and hospital care, and medication-monitoring teams that may include clinical pharmacists. Our broader medical billing services for U.S. hospitals, clinics, and physician groups are designed to connect coding accuracy, documentation, submission, denial follow-up, and A/R management in one workflow.
Using Results to Support Patient Care
Urine drug testing works best when patients understand why it is being done, what is included in the test, and how the result may affect their treatment. A result should not be looked at on its own. It should be considered with the patient’s medical history, medications, symptoms, and other relevant clinical information.
If a result is unexpected, it should start a conversation rather than a judgment. The provider may review the patient’s medications, check with the laboratory, or order confirmatory testing before changing the care plan. The CDC specifically recommends using unexpected toxicology results to improve patient safety rather than dismissing a patient from care.
Make UDS Documentation as Clear as the Clinical Decision
Urine drug testing may begin with a clinical need, but unclear orders, incorrect test-method coding, missing medical necessity, and payer-specific requirements can still create preventable denials. RCMGen helps U.S. hospitals, clinics, and physician groups connect documentation, coding, clean-claim submission, denial follow-up, and A/R recovery without adding unnecessary administrative work to the clinical team.
Get a free revenue Audit Free Instant Revenue Audit for Hospitals and Clinics – RCMGen, Explore physician billing services Physician Billing and Clinic RCM Services | RCMGen